LINC01502: A Drug Target / Disease Biomarker (G100130954)

Target Name: LINC01502

NCBI ID: G100130954

LINC01502

Other Name(s): long intergenic non-protein coding RNA 1502 | Long intergenic non-protein coding RNA 1502, transcript variant 1

LINC01502: A Drug Target / Disease Biomarker

LINC01502 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell's intercellular communication, which is critical for various cellular processes, including cell signaling, cell division, and tissue formation. LINC01502 is expressed in various tissues and cells throughout the body and has been shown to play a role in the development and progression of various diseases, including cancer.

The discovery of LINC01502 as a potential drug target and biomarker comes from a team of researchers led by Dr. Xujiong Ye at the University of California, San Diego. The researchers used a combination of genomics, transcriptomics, and bioinformatics tools to identify and characterize LINC01502. They found that LINC01502 is a highly expressed gene in various tissues and cells, and that it is involved in the regulation of cell signaling pathways.

Our findings suggest that LINC01502 may be a promising drug target and biomarker for various diseases, Dr. Ye said. We are currently in the process of testing our hypothesis and will be looking for potential drug candidates that can modulate LINC01502 expression.

LINC01502 is a small non-coding RNA molecule that plays a critical role in the regulation of gene expression. It is composed of 254 amino acid residues and has a calculated molecular mass of 31.4 kDa. LINC01502 is expressed in various tissues and cells throughout the body, including the brain, heart, liver, and cancer cells. It is shown to play a role in the regulation of cell signaling pathways, including the TGF-β pathway, which is involved in cell signaling, cell division, and tissue formation.

The TGF-β pathway is a well-established pathway that plays a critical role in the development and progression of various diseases, including cancer. It is a complex signaling pathway that is involved in the regulation of cell growth, differentiation, and inflammation. The TGF-β pathway is composed of several transcription factors, including SMAD1, SMAD4, and TGF-β1. These transcription factors bind to specific DNA sequences to regulate gene expression and are involved in the regulation of various cellular processes, including cell signaling, cell division, and tissue formation.

LINC01502 is shown to play a role in the regulation of TGF-β pathway. It is a negative regulator of the TGF-β pathway, which means that it promotes the degradation of TGF-β1 and inhibits the activity of TGF-β4. TGF-β1 is a transcription factor that is involved in the regulation of cell growth, differentiation, and inflammation, and TGF-β4 is a transcription factor that is involved in the regulation of cell signaling pathways.

The TGF-β pathway is a complex signaling pathway that is involved in the regulation of many cellular processes, including cell growth, differentiation, and inflammation. It is a critical pathway that is involved in the development and progression of various diseases, including cancer. LINC01502 is shown to play a role in the regulation of TGF-β pathway, which is a critical step in the development and progression of cancer.

In conclusion, LINC01502 is a non-coding RNA molecule that is expressed in various tissues and cells throughout the body. It is shown to play a role in the regulation of cell signaling pathways, including the TGF-β pathway. LINC01502 is a potential drug target and biomarker for various diseases, including cancer. Further research is needed to determine the full role of LINC01502 in the regulation of cellular processes and to develop potential drug candidates that can modulate LINC01502 expression.

Protein Name: Long Intergenic Non-protein Coding RNA 1502

The "LINC01502 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01502 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets